Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Aug 20, 2025
Trial Information
Current as of August 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study is looking at how well three different vaccines protect against certain types of bacteria that can cause serious infections, specifically pneumococcal disease. Researchers want to see if these vaccines help the body produce strong antibodies—proteins that fight off bacteria—especially against a group called serogroup 33.
The study is open to healthy adults between the ages of 65 and 74 who have never had a pneumococcal vaccine before and do not have any conditions or medications that weaken the immune system. Participants will receive one of the three vaccines, and doctors will then check how well their antibodies can kill the bacteria. This study is not yet recruiting but aims to help improve vaccines for better protection in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy adult
- Exclusion Criteria:
- • No prior history of pneumococcal vaccination
- • No immunosuppressing medications or chronic diseases that affect immune function
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported